A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1152 participants.
Also called NCT05929079
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,152 participants
- Sponsor
- Registry
-
NCT05929079
-
- Other papers using this trial's data
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Brazil, India, Mexico, Romania, Spain
- Registry status
- Completed
Technical summary
Registry record NCT05929079. Randomized; double masking; primary purpose treatment. Start 2023-07-11 (actual); primary completion 2026-06-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
- Acronym
- TRIUMPH-2
- Condition
- Type 2 Diabetes
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Obstructive Sleep Apnea
- Intervention (Drug)
- Retatrutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05929079- Content hash
c556c829ecb67a9f68b44ba329a4084e3fe5b742a606f28aa8b5afc320e6f35c